| 摘要 |
Disclosed are PEG-modified "interleukin-6" derivatives (PEG-IL-6) having an extended plasma half-life, as well as enhanced in vivo IL-6 biological activities. Methods for producing the modified glycosylated and unglycosylated IL-6 proteins or polypeptides, as well as, for their use in treating hematopoietic disorders and difficiencies, particularly acute thrombocytopenia, are also disclosed. The PEG is for example in the form of the formula: (see formula 1) (wherein n and m are each an integer of 7 to 600, and R1 and R2 are lower alkyl).
|
